This graphic demonstrates how STING-NPs enhance uptake of cGAMP. (Jennifer Fairman/Fairman Studios)
New research builds on Nobel-winning immune checkpoint blockade work
Immunotherapy’s promise in the fight against cancer drew international attention after two scientists won a Nobel Prize this year for unleashing the ability of the immune system to eliminate tumor cells.
But their approach, which keeps cancer cells from shutting off the immune system’s powerful T-cells before they can fight tumors, is just one way to use the body’s natural defenses against deadly disease. A team of Vanderbilt University bioengineers today announced a major breakthrough in another: penetrating tumor-infiltrating immune cells and flipping on a switch that tells them to start fighting. The team designed a nanoscale particle to do that and found early success using it on human melanoma tissue.
“Tumors are pretty conniving and have evolved many ways to evade detection from our immune system,” said John T. Wilson, assistant professor of chemical and biomolecular engineering and biomedical engineering. “Our goal is to rearm the immune system with the tools it needs to destroy cancer cells.
“Checkpoint blockade has been a major breakthrough, but despite the huge impact it continues to have, we also know that there are a lot of patients who don’t respond to these therapies. We’ve developed a nanoparticle to find tumors and deliver a specific type of molecule that’s produced naturally by our bodies to fight off cancer.”
That molecule is called cGAMP, and it’s the primary way to switch on what’s known as the stimulator of interferon genes (STING) pathway: a natural mechanism the body uses to mount an immune response that can fight viruses or bacteria or clear out malignant cells. Wilson said his team’s nanoparticle delivers cGAMP in a way that jump-starts the immune response inside the tumor, resulting in the generation of T-cells that can destroy the tumor from the inside and also improve responses to checkpoint blockade.
While the Vanderbilt team’s research focused on melanoma, their work also indicates that this could impact treatment of many cancers, Wilson said, including breast, kidney, head and neck, neuroblastoma, colorectal and lung cancer.
His findings appear today in a paper titled “Endosomolytic Polymersomes Increase the Activity of Cyclic Dinucleotide STING Agonists to Enhance Cancer Immunotherapy” in the journal Nature Nanotechnology.
Daniel Shae, a Ph.D. student on Wilson’s team and first author of the manuscript, said the process began with developing the right nanoparticle, built using “smart” polymers that respond to changes in pH that he engineered to enhance the potency of cGAMP. After 20 or so iterations, the team found one that could deliver cGAMP and activate STING efficiently in mouse immune cells, then mouse tumors and eventually human tissue samples.
“That’s really exciting because it demonstrates that, one day, this technology may have success in patients,” Shae said.
Learn more:Â Nanoparticle targets tumor-infiltrating immune cells, flips switch telling them to fight
The Latest on: Cancer Immunotherapy
via Google News
The Latest on: Cancer Immunotherapy
- Study: New immunotherapy shows promise in targeting pancreatic cancer tumorson June 20, 2022 at 2:00 pm
Dr. Emerson Lim, an Oncologist with Spectrum Health, explains how this particular type of immunotherapy shrank a woman's pancreatic cancer tumors, "So this is particularly excitin ...
- In a Small Study, Experimental Immunotherapy Drug for Rectal Cancer has a High Success Rateon June 20, 2022 at 10:20 am
Dostarlimab is a monoclonal antibody, a type of immunotherapy, made by GlaxoSmithKline and approved by the FDA in April 2021 for endometrial cancer in adults. It helps a patient’s immune system ...
- Onward Therapeutics Made a Second Strategic Equity Investment in Emercell for Their NK Cell Technology in Cancer Immunotherapyon June 19, 2022 at 9:00 pm
EPALINGES, Switzerland and MONTPELLIER, France, June 20, 2022 /PRNewswire/ -- Onward Therapeutics SA (Onward Therapeutics) and Emercell SAS (Emercell) announced today the recent exercise of Onward The ...
- Immunotherapy booster produces 10,000 times more cancer-fighting cellson June 16, 2022 at 8:21 pm
Researchers at Washington University in St. Louis have found that adding a booster protein can significantly improve the outcome of cancer immunotherapy. Tests in mice showed the protein produced ...
- Unheard of: Immunotherapy drug that in trial cured this cancer every timeon June 16, 2022 at 4:00 am
In a clinical trial at Memorial Sloan Kettering Cancer Center, all patients who had been diagnosed with a specific form of rectal cancer had their disease cured.
- Sakti Chakrabarti, MD, on Using Liquid Biopsy to Predict Immunotherapy Response in Pancreatic Canceron June 16, 2022 at 3:00 am
Detection of the microsatellite instability-high (MSI-H) signature by plasma-based testing predicted response to immunotherapy in patients with pancreatic cancer, researchers reported. Because ...
- Dogs inhale immunotherapy to test lung cancer treatmenton June 9, 2022 at 11:51 am
A protein that the body naturally produces could become an important new immunotherapy drug in the cache of cancer-fighting tools available to oncologists. UC Davis cancer researchers for both ...
- Exploring why some cancer patients don't respond to immunotherapyon June 9, 2022 at 9:20 am
Why doesn't every cancer patient respond to immunotherapy? That's the question that researcher Daniel Peeper is looking to answer. His research group tries to identify genes that play a role in ...
- Cancer and immunotherapy – a game of cat and mouseon June 8, 2022 at 5:00 pm
Why doesn’t every cancer patient respond to immunotherapy? That’s the question that researcher Daniel Peeper is looking to answer. His research group tries to identify genes that play a role in ...
- Cancer Disappeared In All Patients Involved In Small Immunotherapy Drug Trialon June 8, 2022 at 5:35 am
Cancer clinical trials include treatment, prevention, screening, supportive and palliative care and natural history studies. Clinical trial success rates vary greatly, but oncology drugs are the ...
via Bing News